Caspofungin: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Caspofungin''' ([[International Nonproprietary Name|INN]]<ref>[http://www.emea.europa.eu/htms/human/epar/c.htm European Medicines Agency's list of authorised medicines for human use (C)]</ref>) (brand name '''Cancidas''' worldwide) is a lipopeptide [[Antifungal medication|antifungal]] drug from [[Merck & Co.|Merck & Co., Inc.]]. It is a member of a new class of antifungals termed the [[echinocandin]]s. It works by inhibiting the [[enzyme]] [[1,3-Beta-glucan synthase|(1→3)-β-<small>D</small>-glucan synthase]] and thereby disturbing the integrity of the fungal [[cell wall]]. Caspofungin was the first inhibitor of fungal (1→3)-β-<small>D</small>-glucan synthesis to be approved by the United States Food and Drug Administration.<ref>{{cite journal|title=Caspofungin|author=Deresinski SC|year=2003|volume=36|issue=11|pages=1445–1457|doi=10.1086/375080|journal=Clin Infect Dis|pmid=12766841|author-separator=,|author2=Stevens DA}}</ref> | |||
Caspofungin is administered [[intravenously]]. | |||
==Category== | ==Category== |
Revision as of 04:08, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Caspofungin (INN[1]) (brand name Cancidas worldwide) is a lipopeptide antifungal drug from Merck & Co., Inc.. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the first inhibitor of fungal (1→3)-β-D-glucan synthesis to be approved by the United States Food and Drug Administration.[2] Caspofungin is administered intravenously.
Category
Antifungal
US Brand Names
CANCIDAS®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
References
- ↑ European Medicines Agency's list of authorised medicines for human use (C)
- ↑ Deresinski SC; Stevens DA (2003). "Caspofungin". Clin Infect Dis. 36 (11): 1445&ndash, 1457. doi:10.1086/375080. PMID 12766841. Unknown parameter
|author-separator=
ignored (help)